Association of Genetic Variants of the Chemokine Receptor CCR5 and Its Ligands, RANTES and MCP-2, with Outcome of HCV Infection

Hepatology

Volumn 38, Issue 6, 2003, Pages 1468-1476

  Hellier, Simon ^a   Frodsham, Angela J ^a   Hennig, Branwen J W ^a   Klenerman, Paul ^d   Knapp, Suzanne ^b   Ramaley, Patricia ^a   Satsangi, Jack ^c   Wright, Mark ^b   Zhang, Lyna ^a   Thomas, Howard C ^b   Thursz, Mark ^b   Hill, Adrian V S ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b ST MARY S HOSPITAL   (United Kingdom)

^c WESTERN GENERAL HOSPITAL   (United Kingdom)

^d UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CCR2; CHEMOKINE RECEPTOR CCR3; CHEMOKINE RECEPTOR CCR5; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MONOCYTE CHEMOTACTIC PROTEIN 1; MONOCYTE CHEMOTACTIC PROTEIN 2; RANTES;

ARTICLE; COHORT ANALYSIS; CONFIDENCE INTERVAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IMMUNE RESPONSE; LYMPHOCYTE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROMOTER REGION;

EID: 0344796403     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hep.2003.09.027     Document Type: Article

References (40)

1. World Health Organisation. Hepatitis C: global prevalence. Weekly Epidemiol Rec 1997;72:341-343.
2. Poynard T, Marcellin P, Lee SS, Niederau C, Minuk GS, Ideo G, Bain V, et al. Randomised trial of interferon α2b plus ribavirin for 48 weeks or for 24 weeks versus interferon α2b plus placebo for 48 weeks for the treatment of chronic infection with hepatitis c virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet 1998;352:1426-1432.
3. McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, Goodman ZD, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 1998;339:1485-1492.
4. Murphy PM. The molecular biology of leukocyte chemoattractant receptors [Review]. Annu Rev Immunol 1994;12:593-633.
5. Choe H, Farzan M, Sun Y, Sullivan N, Rollins B, Ponath PD, Wu L, et al. The β-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates. Cell 1996;85:1135-1148.
6. Dragic T, Litwin V, Allaway GP, Martin SR, Huang Y, Nagashima KA, Cayanan C, et al. HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5. Nature 1996;381:667-673.
7. Liu R, Paxton WA, Choe S, Ceradini D, Martin SR, Horuk R, Mac Donald ME, et al. Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell 1996;86:367-377.
8. Zimmerman PA, Buckler-White A, Alkhatib G, Spalding T, Kubofcik J, Combadiere C, Weissman D, et al. Inherited resistance to HIV-1 conferred by an inactivating mutation in CC chemokine receptor 5: studies in populations with contrasting clinical phenotypes, defined racial background, and quantified risk. Mol Med 1997;3:23-36.
9. Dean M, Carrington M, Winkler C, Huttley GA, Smith MW, Allikmets R, Goedert JJ, et al. Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Hemophilia Growth and Development Study, Multicenter AIDS Cohort Study, Multicenter Hemophilia Cohort Study, San Francisco City Cohort, ALIVE Study. Science 1996;273:1856-1862.
10. Michael NL, Chang G, Louie LG, Mascola JR, Dondero D, Birx DL, Sheppard HW, et al. The role of viral phenotype and CCR-5 gene defects in HIV-1 transmission and disease progression. Nat Med 1997;3:338-340.
11. Tsai SL, Liaw YF, Chen MH, Huang CY, Kuo GC. Detection of type 2-like T-helper cells in hepatitis C virus infection: implications for hepatitis C virus chronicity. HEPATOLOGY 1997;25:449-458.
12. Napoli J, Bishop GA, McGuinness PH, Painter DM, McCaughan GW. Progressive liver injury in chronic hepatitis C infection correlates with increased intrahepatic expression of Th1-associated cytokines. HEPATOLOGY 1996;24:759-765.
13. Bonecchi R, Bianchi G, Bordignon PP, D'Ambrosio D, Lang R, Borsatti A, Sozzani S, et al. Differential expression of chemokine receptors and chemotactic responsiveness of type 1 T helper cells (Th1s) and Th2s. J Exp Med 1998;187:129-134.
14. Shields PL, Morland CM, Salmon M, Qin S, Hubscher SG, Adams DH. Chemokine and chemokine receptor interactions provide a mechanism for selective T cell recruitment to specific liver compartments within hepatitis C-infected liver. J Immunol 1999;163:6236-6243.
15. Ishak K, Baptista A, Bianchi L, Callea F, De Groote J, Gudat F, Denk H, et al. Histological grading and staging of chronic hepatitis [Review]. J Hepatol 1995;22:696-699.
16. Strieter RM, Standiford TJ, Huffnagle GB, Colletti LM, Lukacs NW, Kunkel SL. "The good, the bad, and the ugly." The role of chemokines in models of human disease [Review]. J Immunol 1996;156:3583-3586.
17. Kurihara T, Warr G, Loy J, Bravo R. Defects in macrophage recruitment and host defense in mice lacking the CCR2 chemokine receptor. J Exp Med 1997;186:1757-1762.
18. Kostrikis LG, Huang Y, Moore JP, Wolinsky SM, Zhang L, Guo Y, Deutsh L, et al. A chemokine receptor CCR2 allele delays HIV-1 disease progression and is associated with a CCR5 promoter mutation. Nat Med 1998;4:350-353.
19. Smith MW, Dean M, Carrington M, Winkler C, Huttley GA, Lomb DA, Goedert JJ, et al. Contrasting genetic influence of CCR2 and CCR5 variants on HIV-1 infection and disease progression. Hemophilia Growth and Development Study (HGDS), Multicenter AIDS Cohort Study (MACS), Multicenter Hemophilia Cohort Study (MHCS), San Francisco City Cohort (SFCC), ALIVE Study. Science 1997;277:959-965.
20. Combadiere C, Ahuja SK, Murphy PM. Cloning and functional expression of a human eosinophil CC chemokine receptor. J Biol Chem 1995;270:16491-16494.
21. Daugherty BL, Siciliano SJ, DeMartino JA, Malkowitz L, Sirotina A, Springer MS. Cloning, expression, and characterization of the human eosinophil eotaxin receptor. J Exp Med 1996;183:2349-2354.
22. Zimmermann N, Bernstein JA, Rothenberg ME. Polymorphisms in the human CC chemokine receptor-3 gene. Biochim Biophys Acta 1998;1442:170-176.
23. Kato H, Tsuchiya N, Izumi S, Miyamasu M, Nakajima T, Kawasaki H, Hirai K, et al. New variations of human CC-chemokine receptors CCR3 and CCR4. Genes Immun 1999;1:97-104.
24. Liu H, Chao D, Nakayama EE, Taguchi H, Goto M, Xin X, Takamatsu JK, et al. Polymorphism in RANTES chemokine promoter affects HIV-1 disease progression. Proc Natl Acad Sci U S A 1999;96:4581-4585.
25. Fryer AA, Spiteri MA, Bianco A, Hepple M, Jones PW, Strange RC, Makki R, et al. The -403 G→A promoter polymorphism in the RANTES gene is associated with atopy and asthma. Genes Immun 2000;1:509-514.
26. An P, Nelson GW, Wang L, Donfield S, Goedert JJ, Phair J, Vlahov D, et al. Modulating influence on HIV/AIDS by interacting RANTES gene variants. Proc Natl Acad Sci U S A 2002;99:10002-10007.
27. Bluman EM, Bartynski KJ, Avalos BR, Caligiuri MA. Human natural killer cells produce abundant macrophage inflammatory protein-1 α in response to monocyte-derived cytokines. J Clin Invest 1996;97:2722-2727.
28. Al-Sharif FM, Makki RF, Ollier WE, Hajeer AH. A new microsatellite marker within the promoter region of the MIP-1A gene. Immunogenetics 1999;49:740-741.
29. Loetscher P, Seitz M, Clark-Lewis I, Baggiolini M, Moser B. Monocyte chemotactic proteins MCP-1, MCP-2, and MCP-3 are major attractants for human CD4+ and CD8+ T lymphocytes. FASEB J 1994;8:1055-1060.
30. Taub DD, Proost P, Murphy WJ, Anver M, Longo DL, Van Damme J, Oppenheim JJ. Monocyte chemotactic protein-1 (MCP-1), -2, and -3 are chemotactic for human T lymphocytes. J Clin Invest 1995;95:1370-1376.
31. Czaja MJ, Geerts A, Xu J, Schmiedeberg P, Ju Y. Monocyte chemoattractant protein 1 (MCP-1) expression occurs in toxic rat liver injury and human liver disease. J Leuk Biol 1994;55:120-126.
32. Marra F, Romanelli RG, Giannini C, Failli P, Pastacaldi S, Arrighi MC, Pinzani M, et al. Monocyte chemotactic protein-1 as a chemoattractant for human hepatic stellate cells. HEPATOLOGY 1999;29:140-148.
33. Rovin BH, Lu L, Saxena R. A novel polymorphism in the MCP-1 gene regulatory region that influences MCP-1 expression. Biochem Biophys Res Commun 1999;259:344-348.
34. McManus C, Berman JW, Brett FM, Staunton H, Farrell M, Brosnan CF. MCP-1, MCP-2 and MCP-3 expression in multiple sclerosis lesions: an immunohistochemical and in situ hybridization study. J Neuroimmunol 1998;86:20-29.
35. Van Coillie E, Proost P, Van AI, Struyf S, Polfliet M, DeMeester I, Harvey DJ, et al. Functional comparison of two human monocyte chemotactic protein-2 isoforms, role of the amino-terminal pyroglutamic acid and processing by CD26/dipeptidyl peptidase IV. Biochemistry 1998;37:12672-12680.
36. Thursz M, Yallop R, Goldin R, Trepo C, Thomas HC. Influence of MHC class II genotype on outcome of infection with hepatitis C virus. The HENCORE group. Hepatitis C European Network for Cooperative Research. Lancet 1999;354:2119-2124.
37. Hennig BJW, Hellier S, Frodsham AJ, Zhang L, Klenerman P, Knapp S, Wright M, et al. Association of low-density lipoprotein receptor polymorphisms and outcome of hepatitis C infection. Genes Immun 2002;3:359-367.
38. Woitas RP, Ahlensteil G, Iwan A, Rockstroh JK, Brackmann HH, Kupfer B, Matz B, et al. Frequency of the HIV-Protective CC Chemokine Receptor-Δ 32/Δ32 Genotype is Increased in Hepatitis C. Gastroenterology. 2002;122:1721-1728.
39. Promrat K, McDermott DH, Gonzalez, CM, Kleiner DE, Koziol DE, Lessie M, Merrell M, et al. Associations of chemokine system polymorphisms with clinical outcomes and treatment responses of chronic hepatitis C. Gastroenterology 2003;124:352-360.
40. Samson M, Labbe O, Mollereau C, Vassart G, Parmentier M. Molecular cloning and functional expression of a new human CC-chemokine receptor gene. Biochemistry 1996;35:3362-3367.